The FDA has just approved Jardiance and Synjardy to treat type 2 diabetes in children aged 10 and above
With rising cases of pediatric type 2 diabetes and limited treatment options, these new therapies bring hope
Empagliflozin, the active ingredient in both drugs, works by increasing the excretion of glucose in the urine
A clinical trial demonstrated that Empagliflozin significantly reduced hemoglobin A1c and fasting plasma glucose compared to placebo
While Empagliflozin shares similar side effects with adults, pediatric patients showed a higher risk of hypoglycemia
These drugs should not be used in certain situations, such as severe kidney problems, metabolic acidosis, or type 1 diabetes due to potential health risks
These treatments received priority review designations, emphasizing their significance in treating this serious condition
With these FDA approvals, we're moving toward a future where type 2 diabetes can be more effectively managed in children